|BioDelivery Sciences International, Inc.|
801 Corporate Center Drive
United States - Map
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapeutics in the areas of pain management and oncology supportive care. The company uses its patented BioErodible MucoAdhesive (BEMA) drug delivery technology that consists of a small, bi-layered erodible polymer film for application to the buccal mucosa in the development of its products. Its products include ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in opioid tolerant adult patients with cancer; BEMA Buprenorphine that is in Phase III trial for the treatment of moderate to severe chronic pain in a mixed opioid naïve and opioid experienced population; BEMA Buprenorphine/Naloxone, which is in development stage for the treatment of opioid dependence; and BEMA Granisetron for the prevention of nausea and vomiting associated with cancer therapies. The company has a licensing and development agreement with Endo Pharmaceuticals, Inc. to develop and commercialize BEMA Buprenorphine. BioDelivery Sciences International, Inc. was founded in 1997 and is headquartered in Raleigh, North Carolina.
|BioDelivery Sciences International, Inc.’s ISS Governance QuickScore as of Dec 1, 2013 is 6. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 5; Compensation: 4.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Francis E. O'Donnell Jr., M.D.,
Exec. Chairman, Member of Exec. Subcommittee and Member of Risk Management Committee
|Dr. Mark A. Sirgo Pharm.D.,
Chief Exec. Officer, Pres, Chief Scientific Officer, Exec. Director, Member of Exec. Subcommittee and Member of Risk Management Committee
|Mr. James A. McNulty CPA,
Sr. VP of Fin. and Treasurer
|Dr. Andrew L. Finn Pharm.D.,
Exec. VP of Product Devel.
|Mr. Ernest Robert De Paolantonio CPA, MBA,
Chief Financial Officer and Corp. Sec.
|Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|